Midday Gainers

Loading...
Loading...

Celldex Therapeutics CLDX +29% - Late Friday, the company announced interim results of its Phase 2 ReACT study of rindopepimut in EGFRvIII-positive glioblastoma (GBM), showing gains in survival rates.

Amicus Therapeutics FOLD +15% - Shares are up sharply Monday as the company announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat") for Fabry disease.

Baker Hughes Inc. BHI +12% - On Monday, Halliburton confirmed it will buy Baker Hughes for $34.6 billion.

Exterran Holdings Inc. EXH +7% - On Monday the company’s board of directors announced plans to pursue a plan to separate the company's international contract operations, international aftermarket services and global fabrication businesses into a stand alone, publicly traded company (SpinCo), resulting in two independent companies.

Allergan Inc. AGN + 6% - Actavis Plc announced Monday that they will acquire Allergan for $66 billion or $129 per share.

Posted In: Movers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...